MoonLake Immunotherapeutics's Q2 net loss widens

Overview

• MoonLake ends Q2 with $425.1 mln in cash, bolstered by $500 mln financing

• R&D expenses rise to $49.8 mln, supporting clinical trial expansions

• Phase 3 VELA program for HS on track, significant milestones expected

Outlook

• Around September 2025: R&D Day to present top-line results for the HS Phase 3 VELA program

• Q4 2025: Primary endpoint readout of the Phase 2 LEDA trial in PPP

• Q1 2026: Primary endpoint readout of the Phase 2 S-OLARIS trial in axSpA

• H1 2026: Primary endpoint readout of Phase 3 VELA-TEEN trial in adolescent HS

• H1 2026: Primary endpoint readout of Phase 2 IZAR trial in PsA

Result Drivers

• R&D EXPENSES - Increase driven by contract research and manufacturing costs, consulting expenses, and personnel-related costs for clinical trials

• FINANCIAL POSITION - $500 mln non-dilutive financing agreement with Hercules Capital strengthens cash position and supports clinical objectives

• CLINICAL TRIAL PROGRESS - Phase 3 VELA program in HS and Phase 2 LEDA trial in PPP progressing well, expected to drive future growth

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 16 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for MoonLake Immunotherapeutics is $74.50, about 28.4% above its August 4 closing price of $53.32

Press Release: ID:nGNE6sBWth